Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial
With long-term follow-up, atezolizumab monotherapy demonstrated clinically meaningful efficacy with durable responses in a subset of patients with metastatic UC; there were no new safety signals.
Authors
- Margitta Retz
- D Castellano
- Peter H. O’Donnell (ORCID: https://orcid.org/0000-0003-2650-0049)
- Yi Shi (ORCID: https://orcid.org/0000-0003-2530-410X)
- A. Necchi
- Y. Loriot
- Michiel S. van der Heijden (ORCID: https://orcid.org/0000-0002-4407-7881)
- P. Grivas
- Erik T. Goluboff (ORCID: https://orcid.org/0000-0001-9446-0478)
- Ignacio Durán (ORCID: https://orcid.org/0000-0001-8571-7163)
- José Luis Perez‐Gracia (ORCID: https://orcid.org/0000-0003-4941-9075)
- Srikala S. Sridhar (ORCID: https://orcid.org/0000-0002-6994-1285)
- Jean Hoffman‐Censits (ORCID: https://orcid.org/0000-0002-6970-6509)
- Alexandra Drakaki (ORCID: https://orcid.org/0000-0001-8865-3548)
- Daniel Peter Petrylak (ORCID: https://orcid.org/0000-0001-6165-5797)
- S. Mariathasan
- Dean F. Bajorin (ORCID: https://orcid.org/0000-0003-4001-7088)
- Joaquim Bellmunt (ORCID: https://orcid.org/0000-0003-2328-3421)
- M.D. Galsky
- Evan Y. Yu (ORCID: https://orcid.org/0000-0002-1510-8044)
- Robert Dreicer (ORCID: https://orcid.org/0000-0002-0552-6912)
- Thomas Powles
- H.A. Burris
- J. E. Rosenberg
Institutions
- Université Paris-Sud (FR)
- Cleveland Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Vita-Salute San Raffaele University (IT)
- University of California, Los Angeles (US)
- Queen Mary University of London (GB)
- Université Paris-Saclay (FR)
- Dutch Cancer Society (NL)
- Princess Margaret Cancer Centre (CA)
- Yale Cancer Center (US)
- The Netherlands Cancer Institute (NL)
- University of Chicago (US)
- Research Institute Hospital 12 de Octubre (ES)
- Fred Hutch Cancer Center (US)
- Sarah Cannon (US)
- Dana-Farber Cancer Institute (US)
- Clinica Universidad de Navarra (ES)
- Hospital Universitario Virgen del Rocío (ES)
- Sidney Kimmel Comprehensive Cancer Center (US)
- University of Virginia Cancer Center
- University of Virginia (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103972
- Citations
- 23
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 13.17
Funders
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Gilead Sciences
- Celgene
- F. Hoffmann-La Roche
- Array BioPharma
- Vertex Pharmaceuticals
- TG Therapeutics
- Agios Pharmaceuticals
- HCA Healthcare
- Jounce Therapeutics
- Incyte
- XBiotech
- Revolution Medicines
- Moderna
- Seagen
- Astellas Pharma
- National Institutes of Health
- Genentech
- EMD Serono
- Foundation Medicine
- National Cancer Institute